BusinessSienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125By Nasdaq OMXFeb 14, 2018, 2:05 PM UTC
BusinessSienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120By Nasdaq OMXOct 24, 2017, 1:05 PM UTC
